Showing results (171-180 of 178) with videos related to
Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 178 results.
Molecular Cancer Therapeutics|September 24, 2020
Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid CancerJuniper A Scribner, Jennifer G Brown, Thomas Son, et al.Molecular Cancer Therapeutics|June 6, 2018
Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal CancerPaul A Moore, Kalpana Shah, Yinhua Yang, et al.Nature Medicine|April 3, 2023
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trialEugene Shenderov, Angelo M De Marzo, Tamara L Lotan, et al.Journal for Immunotherapy of Cancer|April 13, 2022
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trialCharu Aggarwal, Amy Prawira, Scott Antonia, et al.Molecular Cancer Therapeutics|May 5, 2022
Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing TumorsJuniper A Scribner, Stuart W Hicks, Kerstin W Sinkevicius, et al.Nature Medicine|October 19, 2023
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trialJason J Luke, Manish R Patel, George R Blumenschein, et al.Oncology (Williston Park, N.Y.)|April 27, 2023
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel Vt Catenacci, Yoon-Koo Kang, Hope E Uronis, et al.Antibodies (Basel, Switzerland)|September 28, 2019
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of CancerAdam R Root, Wei Cao, Bilian Li, et al.Pageof 18